Bausch Health Taps Jonathan Sadeh as Chief Medical Officer

Dow Jones12-02

By Robb M. Stewart

Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development.

Sadeh joins the Canadian pharmaceutical company as executive vice president, chief medical officer and head of R&D. In the role, he will oversee Bausch's entire R&D process, working with the company's scientists and engineers.

Sadeh has more than two decades clinical research and drug development experience as a physician-scientist and pharma-industry leader, Bausch said. Most recently at Bristol-Meyers Squibb he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles, including senior vice president and global programs head for immunology, cardiovascular and neuroscience, immunology therapeutic area head.

The Laval, Quebec, company in late October said it was targeting revenue this year of between $9.5 billion and $9.68 billion. Bausch has rejected debt-restructuring proposals from bondholders as it continues to explore an exit from its Bausch + Lomb subsidiary.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

December 02, 2024 08:27 ET (13:27 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488679598?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488679598","market":"sh","top_or_hot":-1,"title":"Bausch Health Taps Jonathan Sadeh as Chief Medical Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development. \n</p>\n<p>\n  Sadeh joins the Canadian pharmaceutical company as executive vice president, chief medical officer and head of R&amp;D. In the role, he will oversee Bausch's entire R&amp;D process, working with the company's scientists and engineers. \n</p>\n<p>\n  Sadeh has more than two decades clinical research and drug development experience as a physician-scientist and pharma-industry leader, Bausch said. Most recently at Bristol-Meyers Squibb he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles, including senior vice president and global programs head for immunology, cardiovascular and neuroscience, immunology therapeutic area head. \n</p>\n<p>\n  The Laval, Quebec, company in late October said it was targeting revenue this year of between $9.5 billion and $9.68 billion. Bausch has rejected debt-restructuring proposals from bondholders as it continues to explore an exit from its Bausch + Lomb subsidiary. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 02, 2024 08:27 ET (13:27 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch Health Taps Jonathan Sadeh as Chief Medical Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch Health Taps Jonathan Sadeh as Chief Medical Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Robb M. Stewart \n\n\n \n\n\n  Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development. \n\n\n  Sadeh joins the Canadian pharmaceutical company ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0985481810.HKD","symbol_name":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488679598","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488679598","pubTimestamp":1733146020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development.Sadeh joins the Canadian pharmaceutical company as executive vice president, chief medical officer and head of R&D. In the role, he will oversee Bausch's entire R&D process, working with the company's scientists and engineers.Sadeh has more than two decades clinical research and drug development experience as a physician-scientist and pharma-industry leader, Bausch said. Most recently at Bristol-Meyers Squibb he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles, including senior vice president and global programs head for immunology, cardiovascular and neuroscience, immunology therapeutic area head.The Laval, Quebec, company in late October said it was targeting revenue this year of between $9.5 billion and $9.68 billion. Bausch has rejected debt-restructuring proposals from bondholders as it continues to explore ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4559":"巴菲特持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4588":"碎股","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BMY":"施贵宝","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4581":"高盛持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BHC":"Bausch Health Companies Inc","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4532":"文艺复兴科技持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4534":"瑞士信贷持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0237698245.USD":"富达环球地产基金A","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC"},"translate_title":"Bausch Health任命Jonathan Sadeh为首席医疗官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9,"BMY":0.64},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development. \n\n\n  Sadeh joins the Canadian pharmaceutical company as executive vice president, chief medical officer and head of R&D. In the role, he will oversee Bausch's entire R&D process, working with the company's scientists and engineers. \n\n\n  Sadeh has more than two decades clinical research and drug development experience as a physician-scientist and pharma-industry leader, Bausch said. Most recently at Bristol-Meyers Squibb he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles, including senior vice president and global programs head for immunology, cardiovascular and neuroscience, immunology therapeutic area head. \n\n\n  The Laval, Quebec, company in late October said it was targeting revenue this year of between $9.5 billion and $9.68 billion. Bausch has rejected debt-restructuring proposals from bondholders as it continues to explore an exit from its Bausch + Lomb subsidiary. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2024 08:27 ET (13:27 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488679598"}